Tobias Boch

机构：Heidelberg University, University Hospital Heidelberg, University Medical Centre Mannheim · ORCID：0000-0001-8588-4180

发表论文 95 篇 · 总被引 2816 次 · h-index 24

代表论文

• Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy (2023 · The European Journal of Health Economics · 被引 119)
• Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023 · American Journal of Cardiovascular Drugs · 被引 102)
• Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype (2024 · Nature Genetics · 被引 37)
• Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy (2024 · Nature Communications · 被引 16)
• Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study (2024 · BMC Cancer · 被引 4)
• Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board (2025 · ESMO Open · 被引 3)